Skip to main content
Erschienen in: Journal of Cancer Education 3/2011

01.09.2011

Knowledge, Perceptions, and Motivations Related to HPV Vaccination Among College Women

verfasst von: Megan K. Bendik, Rachel M. Mayo, Veronica G. Parker

Erschienen in: Journal of Cancer Education | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

Little research exists on the factors that affect the uptake patterns of the recently developed Gardasil® vaccine among young women. Human papillomavirus (HPV)-related knowledge, attitudes, beliefs, and behaviors of 18–24-year-old female students (n = 1,975) were assessed via an electronic survey. Mean HPV knowledge score, on a 10-point scale, was 6.8. A weak positive correlation (r (1,976) = 0.123, p < 0.001) was found between knowledge score and having received the vaccine. Parent recommendation, doctor recommendation, and perceiving the consequences of HPV as severe and prevalent were strongly related to previous vaccination. Data suggest a need for increased education about the vaccine and the importance of physician recommendation in increasing vaccine uptake.
Literatur
3.
Zurück zum Zitat Bosch FX, de Sanjose S (2003) Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr 31:3–13PubMed Bosch FX, de Sanjose S (2003) Chapter 1: human papillomavirus and cervical cancer—burden and assessment of causality. J Natl Cancer Inst Monogr 31:3–13PubMed
4.
Zurück zum Zitat Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJF, Meijer CJLM, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 384:518–527CrossRef Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJF, Meijer CJLM, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group (2003) Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 384:518–527CrossRef
5.
Zurück zum Zitat Merck & Co, Inc Gardasil® (2006) Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, Recombinant Whitehouse Station, NJ Merck & Co, Inc Gardasil® (2006) Human papillomavirus quadrivalent (types 6, 11, 16, and 18) vaccine, Recombinant Whitehouse Station, NJ
6.
Zurück zum Zitat Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE (2007) Prevalence of HPV infection among females in the United States. JAMA 297:813–819PubMedCrossRef Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, Markowitz LE (2007) Prevalence of HPV infection among females in the United States. JAMA 297:813–819PubMedCrossRef
8.
Zurück zum Zitat Brewer NT, Fazekas KI (2007) Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 45:107–114PubMedCrossRef Brewer NT, Fazekas KI (2007) Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 45:107–114PubMedCrossRef
9.
Zurück zum Zitat Kahn JA, Rosenthal SL, Hamann T, Bernstein DI (2003) Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 14:300–306PubMedCrossRef Kahn JA, Rosenthal SL, Hamann T, Bernstein DI (2003) Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 14:300–306PubMedCrossRef
10.
Zurück zum Zitat Hoover DR, Carfioli B, Moench EA (2000) Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int 21:375–391PubMedCrossRef Hoover DR, Carfioli B, Moench EA (2000) Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials. Health Care Women Int 21:375–391PubMedCrossRef
11.
Zurück zum Zitat Boehner CW, Howe SR, Bernstein DI, Rosenthal SL (2003) Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis 30:774–778PubMedCrossRef Boehner CW, Howe SR, Bernstein DI, Rosenthal SL (2003) Viral sexually transmitted disease vaccine acceptability among college students. Sex Transm Dis 30:774–778PubMedCrossRef
12.
Zurück zum Zitat Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L (2000) Acceptability of human papillomavirus immunization. J Women Health Gen-B 9(1):47–50CrossRef Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L (2000) Acceptability of human papillomavirus immunization. J Women Health Gen-B 9(1):47–50CrossRef
13.
Zurück zum Zitat Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M (2007) Human papillomavirus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health 7:304–309PubMedCrossRef Sauvageau C, Duval B, Gilca V, Lavoie F, Ouakki M (2007) Human papillomavirus vaccine and cervical cancer screening acceptability among adults in Quebec, Canada. BMC Public Health 7:304–309PubMedCrossRef
14.
Zurück zum Zitat Crosby R, Schoenberg N, Hopenhayn C, Moore G, Melhan W (2007) Correlates of intent to be vaccinated against human papillomavirus: an exploratory study of college-aged women. Sex Health 4(1):71–73PubMedCrossRef Crosby R, Schoenberg N, Hopenhayn C, Moore G, Melhan W (2007) Correlates of intent to be vaccinated against human papillomavirus: an exploratory study of college-aged women. Sex Health 4(1):71–73PubMedCrossRef
16.
Zurück zum Zitat Becker MH ed (1974) The health belief model and personal health behavior. Health Education Monographs.2:324–473 Becker MH ed (1974) The health belief model and personal health behavior. Health Education Monographs.2:324–473
17.
Zurück zum Zitat SPSS for Windows, Rel. 16.0.1. 2007. Chicago: SPSS Inc SPSS for Windows, Rel. 16.0.1. 2007. Chicago: SPSS Inc
19.
Zurück zum Zitat Cates JR, Brewer NT, Fazekas KI, Mitchell CE, Smith JS (2009) Racial differences in HPV knowledge, HPV vaccine acceptability, and related beliefs among rural, southern women. J Rural Health 25(1):93–97PubMedCrossRef Cates JR, Brewer NT, Fazekas KI, Mitchell CE, Smith JS (2009) Racial differences in HPV knowledge, HPV vaccine acceptability, and related beliefs among rural, southern women. J Rural Health 25(1):93–97PubMedCrossRef
20.
Zurück zum Zitat Lambert EC (2001) College students’ knowledge of human papillomavirus and effectiveness of a brief educational intervention. J Am Board Fam Pract 14(3):178–183PubMed Lambert EC (2001) College students’ knowledge of human papillomavirus and effectiveness of a brief educational intervention. J Am Board Fam Pract 14(3):178–183PubMed
21.
Zurück zum Zitat Hildesheim A, Rolando H (2007) Human papillomavirus vaccine should be given before sexual debut for maximum benefit [Editorial]. J Infect Dis 196:1431–1432PubMedCrossRef Hildesheim A, Rolando H (2007) Human papillomavirus vaccine should be given before sexual debut for maximum benefit [Editorial]. J Infect Dis 196:1431–1432PubMedCrossRef
24.
Zurück zum Zitat Hoffner B (2009) Vaccination against the human papillomavirus: the lessons we have not learned. Vaccine 27:2195–2198PubMedCrossRef Hoffner B (2009) Vaccination against the human papillomavirus: the lessons we have not learned. Vaccine 27:2195–2198PubMedCrossRef
Metadaten
Titel
Knowledge, Perceptions, and Motivations Related to HPV Vaccination Among College Women
verfasst von
Megan K. Bendik
Rachel M. Mayo
Veronica G. Parker
Publikationsdatum
01.09.2011
Verlag
Springer-Verlag
Erschienen in
Journal of Cancer Education / Ausgabe 3/2011
Print ISSN: 0885-8195
Elektronische ISSN: 1543-0154
DOI
https://doi.org/10.1007/s13187-011-0200-8

Weitere Artikel der Ausgabe 3/2011

Journal of Cancer Education 3/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.